{
    "clinical_study": {
        "@rank": "112433", 
        "arm_group": [
            {
                "arm_group_label": "Standard of care", 
                "arm_group_type": "Active Comparator", 
                "description": "Group A: comprises 40 treatment-naive chronic hepatitis c patients who will receive the standard of care treatment: peginterferon Alfa 2a 160 ug once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or \u2265 75 kg, respectively) in divided doses for 48 weeks."
            }, 
            {
                "arm_group_label": "Triple therapy", 
                "arm_group_type": "Experimental", 
                "description": "Group B: comprises 40 treatment-naive chronic HCV patients who will receive oral vitamin D 1mcg once daily plus peginterferon alfa-2a (160ug once weekly) and weight-based ribavirin 1000-1200 mg daily (based on body weight < 75 kg or \u2265 75 kg, respectively) in divided doses for 48 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "Chronic hepatitis C is endemic in Egypt with a high prevalence of the resistant genotype 4.\n      Conventional standard of care treatment has modest response with only 50% sustained\n      virologic response. Recent reports have suggested an augmented response with the addition of\n      vitamin D. This is a prospective randomized trial to assess the effectiveness of adding\n      vitamin D to standard of care for chronic hepatitis C genotype 4."
        }, 
        "brief_title": "Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis c", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis c", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult (male or female), 18 to 65 years of age, with chronic HCV infection\n\n          -  Liver biopsy showing chronic hepatitis with significant fibrosis using Ishak scoring\n             system\n\n          -  Compensated liver disease; serum bilirubin < 1.5 mg/dl, INR no more than 1.5, serum\n             albumin > 3.4, platelet count > 75,000 mm, and no evidence of hepatic decompensation\n             (hepatic encephalopathy or ascites)\n\n          -  Acceptable hematological and biochemical indices (hemoglobin 12.5g/dl for men and 12\n             g/dl for women; neutrophil count 1500/mm3 or more and serum creatinine < 1.5 mg/dl\n\n          -  Patients must be serum hepatitis B surface antigen (HBsAg) negative\n\n          -  Negative Antinuclear Antibodies (ANA) or titer of < 1:160\n\n          -  Serum positive for anti-HCV antibodies and HCV-RNA\n\n          -  Abdominal Ultrasound obtained within 3 months prior to entry in the study\n\n          -  Electrocardiogram for men aged > 40 years and for women aged > 50 years\n\n          -  Normal fundus examination\n\n          -  Proper contraception measure throughout the course of treatment and six months later\n\n          -  Female patients must not breast feed during therapy\n\n        Exclusion Criteria:\n\n          -  Patients who previously received interferon\n\n          -  HgbA1c > 7.5 or history of diabetes mellitus\n\n          -  BMI > 34\n\n          -  Women who are pregnant or breast-feeding\n\n          -  Males whose female partners are either pregnant or of child-bearing potential or not\n             using birth control and are sexually active\n\n          -  Other causes of liver disease including autoimmune hepatitis\n\n          -  Transplant recipients receiving immune suppression therapy\n\n          -  Screening tests positive for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab or anti-HIV Ab\n\n          -  Decompensated cirrhosis, history of variceal bleeding, ascites, hepatic\n             encephalopathy, CTP score > 6 or MELD score > 8\n\n          -  Absolute neutrophil count < 1500 cells/mm3; platelet count < 135,000 cells/mm3;\n             hemoglobin < 12 g/dL for women and < 12.5 g/dL for men; or serum creatinine\n             concentration \u2265 1.5 times ULN\n\n          -  Hypothyroidism or hyperthyroidism not effectively treated with medication\n\n          -  Alcohol consumption of > 40 grams per day or an alcohol use pattern that will\n             interfere with the study\n\n          -  History or other clinical evidence of significant or unstable cardiac disease\n\n          -  History or other clinical evidence of chronic pulmonary disease associated with\n             functional impairment\n\n          -  Serious or severe bacterial infection(s)\n\n          -  History of severe or uncontrolled psychiatric disease, including severe depression,\n             history of suicidal ideation, suicidal attempts or psychosis requiring medication\n             and/or hospitalization\n\n          -  History of uncontrolled severe seizure disorder\n\n          -  History of immunologically mediated disease requiring more than intermittent\n             anti-inflammatory medications for management or that requires frequent or prolonged\n             use of corticosteroids\n\n          -  Patients with clinically significant retinal abnormalities\n\n               -  Subjects receiving vitamin D for any other medical condition.\n\n               -  Subjects with significant active rheumatologic or orthopaedic conditions."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01655966", 
            "org_study_id": "RAIL002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Triple therapy", 
                "description": "Vitamin D: 1mcg once daily 48 weeks Pegylated interferon 160ug once weekly 48 weeks Ribavirin(> 75kg:1200 mg, <75kg:1000mg daily)48 weeks", 
                "intervention_name": "vitamin D +pegylated interferon + ribavirin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Standard of care", 
                "description": "pegylated interferon 160ug once weekly Ribavirin (> 75kg:1200 mg, <75kg:1000mg daily)48 weeks", 
                "intervention_name": "pegylated interferon + ribavirin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins", 
                "Interferons", 
                "Ribavirin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "chronic hepatitis c", 
            "hcv", 
            "vitamin d"
        ], 
        "lastchanged_date": "January 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt"
                }, 
                "name": "National Railway Hospital Center"
            }
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "Vitamin D in Addition to Pegylated Interferon and Ribavirin Compared to Pegylated Interferon and Ribavirin Alone in the Treatment of Chronic Hepatitis C Genotype 4.", 
        "overall_official": [
            {
                "affiliation": "Cairo University", 
                "last_name": "Tamer Elbaz, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Cairo University", 
                "last_name": "Hany Shehab, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Egypt: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Undetectable HCV-RNA 24 weeks after end of treatment.", 
            "measure": "Sustained virologic response", 
            "safety_issue": "No", 
            "time_frame": "72 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01655966"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cairo University", 
            "investigator_full_name": "Hany Shehab", 
            "investigator_title": "Dr", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "undetectable HCV-RNA 4 weeks after commencement of treatment", 
                "measure": "rapid virologic response", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "undetectable HCV-RNA 48 weeks after commencement of treatment", 
                "measure": "End-of-treatment response", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "Adverse events that could be reasonably and temporally associated with administration of drugs", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "72 weeks"
            }, 
            {
                "description": "Early virologic response: undetectable HCV-RNA 12 weeks after commencement of treatment.\nPartial early virologic response: decrease of more than 2login HCV-RNA.\nNo early virologic response: increase, stationary or decreased less than 2log HCV-RNA.", 
                "measure": "early virologic response", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Cairo University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cairo University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}